Kyowa Kirin and Kura Oncology's $1.1B Partnership for Ziftomenib in Global Leukemia Treatment

Kyowa Kirin has made a significant investment of up to $1.1 billion in Ziftomenib, an oral menin inhibitor being developed for the treatment of acute myeloid leukemia (AML) through a strategic collaboration with Kura Oncology[1][2]. The agreement includes a $330 million upfront payment and promises up to $420 million in near-term milestone payments, along with an additional $741 million based on further milestone achievements[1][2]. This partnership enables Kyowa Kirin to gain rights to share U.S. profits and obtain global commercialization rights, while Kura will lead the development, regulatory efforts, and manufacturing in the U.S.[1]. As the companies prepare for a Phase 3 trial in 2025, this funding is crucial for supporting Ziftomenib's path to commercialization as a frontline AML treatment[2].